Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Natalia Ruiz-Negrón"'
Autor:
Brandon K. Bellows, Amit V. Khera, Yiyi Zhang, Natalia Ruiz‐Negrón, Henry M. Stoddard, John B. Wong, Dhruv S. Kazi, Sarah D. de Ferranti, Andrew E. Moran
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 11 (2022)
Background Heterozygous familial hypercholesterolemia (FH) is a common genetic disorder causing premature cardiovascular disease. Despite this, there is no national screening program in the United States to identify individuals with FH or likely path
Externí odkaz:
https://doaj.org/article/fb9dc50b5cab461f9147af0d42850f30
Autor:
Kelsey B. Bryant, James P. Sheppard, Natalia Ruiz‐Negrón, Ian M. Kronish, Valy Fontil, Jordan B. King, Mark J. Pletcher, Kirsten Bibbins‐Domingo, Andrew E. Moran, Richard J. McManus, Brandon K. Bellows
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 15 (2020)
Background Self‐monitoring of blood pressure (SMBP) improves blood pressure (BP) outcomes at 12‐months, but information is lacking on how SMBP affects hypertension care processes and longer‐term BP outcomes. Methods and Results We pooled indivi
Externí odkaz:
https://doaj.org/article/b9031904f0024ddda388963421228770
Autor:
Monika M. Safford, Brandon K. Bellows, Paul Muntner, Adam P. Bress, Catherine G. Derington, George Howard, Andrew E. Moran, Emily B. Levitan, Jian Ying, Swati Sakhuja, Gabriel S. Tajeu, Natalia Ruiz-Negrón, Tom Greene, Jennifer S. Herrick, Ransmond O. Berchie, William S. Weintraub
Publikováno v:
Hypertension. 78
Introduction: If resources are scarce, achieving national SBP control goals will require prioritizing treatment among those likely to benefit. To identify patients with greatest predicted benefit with intensive SBP treatment and estimate population s
Autor:
Carrie McAdam-Marx, Natalia Ruiz-Negrón, Brandon K. Bellows, Curtis Wander, Robert A. Bailey, Jacqueline Pesa
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:304-313
Despite evidence showing the benefits of treatment intensification following an elevated hemoglobin A1c (A1c), clinical inertia, or failure to establish and/or escalate treatment to achieve treatment goals, is a concern among patients diagnosed with
Publikováno v:
Diabetes. 70
Introduction: High patient out-of-pocket (OOP) cost for insulin led to a program limiting OOP to $35/30-day supply in select Medicare Part D plans. This study assessed the association between insulin utilization and insulin OOP cost in Medicare Advan
Publikováno v:
Diabetes. 70
Introduction: Concerns over cost-related non-adherence and high patient out-of-pocket (OOP) costs for insulin has prompted policies limiting insulin copays. This study examines the associations of insulin OOP cost by policy-relevant groupings, with g
Autor:
Ciantel A. Blyler, Joseph E. Ebinger, Andrew E. Moran, Kelsey B. Bryant, Joanne Penko, Laura P. Cohen, Yiyi Zhang, Brandon K. Bellows, Valy Fontil, Kirsten Bibbins-Domingo, Florian Rader, Norma B Moy, Natalia Ruiz-Negrón, Kathleen Lynch, Pamela G. Coxson, Dhruv S. Kazi, Gabriel S. Tajeu
Publikováno v:
Circulation
Background:In LABBPS (Los Angeles Barbershop Blood Pressure Study), pharmacist-led hypertension care in Los Angeles County Black-owned barbershops significantly improved blood pressure control in non-Hispanic Black men with uncontrolled hypertension
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::556c6a703aa45f25a9dca3e396ebdbaa
https://europepmc.org/articles/PMC8206005/
https://europepmc.org/articles/PMC8206005/
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:1140-1141
Autor:
Eric Wittbrodt, Marisa B. Schauerhamer, Sudhir Unni, Junjie Ma, Natalia Ruiz-Negrón, Jeff Hurd, Carrie McAdam-Marx
Publikováno v:
Diabetes, Obesity and Metabolism. 20:468-473
A retrospective cohort study was conducted in patients with type 2 diabetes in an electronic medical record database to compare real-world, 6-month glycated haemoglobin (HbA1c) and weight outcomes for exenatide once weekly with those for dulaglutide
Autor:
Molly B. Conroy, Donald E. Morisky, Jackson T. Wright, Brandon K. Bellows, Jordan B. King, William S. Weintraub, Andrew E. Moran, Dan R. Berlowitz, Lewis E. Kazis, Larry J. Fine, Natalia Ruiz-Negrón, Suzanne Oparil, Srinivasan Beddhu, Jamie Powell, Rachel Hess, Alfred K. Cheung, Adam P. Bress, Zugui Zhang, Jeff Whittle, Mark A. Supiano, Leonardo Tamariz
Publikováno v:
New England Journal of Medicine. 377:745-755
BackgroundIn the Systolic Blood Pressure Intervention Trial (SPRINT), adults at high risk for cardiovascular disease who received intensive systolic blood-pressure control (target